Performance comparison of Bruker MBT Sepsityper® Kit US IVD for culture-independent identification and antimicrobial susceptibility testing from positive blood cultures

Sponsored by: Bruker Microbiology & Infection Diagnostics

C.E. Credits: P.A.C.E. CE ｜ Florida CE

Speaker

Event Date & Time

Date: November 1, 2022

Time: 9:00am (PDT), 12:00pm (EDT), 5:00pm (CET)

Abstract

Rapid and efficient organism identification and antimicrobial susceptibility reports are paramount for patient survival during sepsis. The Bruker MBT Sepsityper^® Kit US IVD allows harvesting of microorganism directly from positive blood cultures and pairs it with the Bruker MALDI Biotyper^® CA System for rapid identification of bacterial isolates using MALDI-TOF technology. Here we compare the accuracy of the MBT Sepsityper^® Kit US IVD for bacterial identification to culture-based methods. Further, as an off-label use of the kit, we compare the antimicrobial susceptibility results for Gram-negative bacteria setup directly using the harvested pellet to the established method in the laboratory. To conclude the webinar, there will be an interactive Q & A session.

Learning Objectives

List three different methods/technologies used to rapidly identify microorganisms directly from positive blood cultures.
Summarize the percent agreement of identifications between MBT Sepsityper^® and standard culture.
Define categorical agreement as stated by CLSI and list the three error categories.
Recall the time savings to the final blood culture report when microorganism identification and AST are acquired using the MBT Sepsityper^® and how this can impact the survival rate for a patient with a BSI.

Any data generated outside the cleared intended use cannot be used for clinical diagnostic purposes.

Webinars will be available for unlimited on-demand viewing after live event.